Pharma Patent Technology Roadmaps: The Complete Intelligence Playbook for IP Teams and Portfolio Managers
How to convert raw patent filings into predictive R&D roadmaps that de-risk pipelines, price M&A targets, and identify white space […]
How to convert raw patent filings into predictive R&D roadmaps that de-risk pipelines, price M&A targets, and identify white space […]
The complete operational guide for pharma IP teams, portfolio managers, and supply chain leads on converting patent intelligence into production
Drug Patent Data Is Your Supply Chain’s Most Accurate Forecasting Tool Read Post »
Part I: The $15 Billion Paradox — A Market That Grows With the Brake On The pharmaceutical excipients market is
NDC Composition Data: The Excipient R&D Roadmap That Cuts Guesswork Read Post »
Every day a blockbuster drug holds patent protection is worth, on average, $8.2 million in revenue. That figure makes the
Executive Summary Between 2023 and 2028, an estimated $356 billion in worldwide branded pharmaceutical sales sit exposed to patent expiration.
Executive Intelligence Brief Biosimilar development is not generic drug development with more paperwork. It is a $100M-to-$300M scientific undertaking that
Biosimilar Reverse Engineering: The Complete Technical, Regulatory, and IP Playbook Read Post »
Executive Summary Every month, the FDA issues a batch of Tentative Approvals (TAs) for generic drug applications. Most market participants
1. What Excipients Actually Are, and Why the Definition Undersells Them The word ‘excipient’ derives from the Latin excipere, meaning
Pharmaceutical Excipients: The Complete IP, Clinical, and Competitive Strategy Guide Read Post »
How European Supplementary Protection Certificates actually work, why their expiry dates keep moving, and what that means for your market
EU SPC Expiry Decoded: The Competitive Playbook Every Pharma Strategist Needs Read Post »
Get fresh news and insights, drug patent expirations & more…